US Stock MarketDetailed Quotes
IKNA Ikena Oncology
- 1.720
- 0.0000.00%
Close Nov 4 16:00 ET
- 1.728
- +0.008+0.47%
Post 19:03 ET
83.00MMarket Cap-1211P/E (TTM)
1.750High1.700Low36.27KVolume1.750Open1.720Pre Close62.65KTurnover0.26%Turnover RatioLossP/E (Static)48.26MShares2.32052wk High0.58P/B23.85MFloat Cap1.22052wk Low--Dividend TTM13.87MShs Float37.610Historical High--Div YieldTTM2.91%Amplitude1.020Historical Low1.727Avg Price1Lot Size
Ikena Oncology Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 31.09%-12.5M | 7.48%-18.3M | -7.60%-79.74M | -23.59%-21.82M | -16.13%-20M | 6.72%-18.14M | 0.00%-19.78M | -23.00%-74.11M | -32.07%-17.66M | 4.29%-17.22M |
| Net income from continuing operations | 19.78%-13.73M | -13.55%-16.15M | 0.87%-68.17M | -38.25%-19.49M | -0.03%-17.34M | 16.48%-17.12M | 15.56%-14.22M | -101.57%-68.77M | -604.00%-14.1M | -19.45%-17.34M |
| Operating gains losses | --0 | --99K | -97.30%5K | --0 | --0 | ---- | ---- | --185K | --0 | --12K |
| Depreciation and amortization | -61.98%92K | -5.19%219K | 35.82%1.02M | 45.24%305K | 13.62%242K | 63.51%242K | 28.33%231K | 38.05%751K | 28.83%210K | 44.90%213K |
| Other non cash items | 34.30%462K | 32.05%445K | 33.59%1.71M | 70.30%562K | 44.92%471K | 8.86%344K | 8.01%337K | 9.28%1.28M | 7.84%330K | 8.33%325K |
| Change In working capital | 93.75%-181K | 30.67%-5.27M | -43.14%-21.67M | -8.10%-6.38M | -110.37%-4.79M | -83.41%-2.9M | -41.35%-7.6M | 54.17%-15.14M | 67.59%-5.9M | 57.62%-2.28M |
| -Change in receivables | 49.24%-501K | -123.57%-157K | -886.25%-2.87M | -2,115.29%-1.88M | 42.49%-666K | -204.11%-987K | 16,550.00%666K | -180.61%-291K | -118.68%-85K | -112.09%-1.16M |
| -Change in prepaid assets | 673.80%2.63M | -220.45%-371K | 106.59%11K | -249.73%-831K | -52.92%992K | 82.78%-458K | 282.25%308K | 94.37%-167K | 265.13%555K | 267.36%2.11M |
| -Change in payables and accrued expense | -289.87%-1.72M | -28.95%-3.76M | -443.50%-7.66M | -301.37%-2.35M | -193.96%-3.3M | 9.40%908K | -91.66%-2.92M | 71.80%2.23M | -134.57%-586K | 638.74%3.51M |
| -Change in other current liabilities | -64.04%-584K | -183.77%-979K | -54.02%-1.99M | -94.38%-657K | -90.94%-632K | -12.66%-356K | -12.38%-345K | -74.59%-1.29M | -12.67%-338K | -11.82%-331K |
| -Change in other working capital | ---- | ---- | 41.35%-9.16M | 87.91%-659K | 81.49%-1.19M | -425.72%-2M | -57.00%-5.31M | 49.59%-15.62M | 73.04%-5.45M | -70.97%-6.4M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 31.09%-12.5M | 7.48%-18.3M | -7.60%-79.74M | -23.59%-21.82M | -16.13%-20M | 6.72%-18.14M | 0.00%-19.78M | -23.00%-74.11M | -32.07%-17.66M | 4.29%-17.22M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -82.72%3.92M | -351.03%-48.74M | 164.61%64.14M | 94.08%20.38M | -10.87%31.89M | 10.71%22.68M | 93.49%-10.81M | -5,541.14%-99.28M | 2,008.91%10.5M | 19,546.74%35.78M |
| Net PPE purchase and sale | 4,525.00%185K | 139.47%60K | 71.07%-414K | -15.15%-266K | --0 | 111.11%4K | -360.61%-152K | 18.69%-1.43M | 58.00%-231K | -514.67%-1.13M |
| Net investment purchase and sale | -83.54%3.73M | -358.03%-48.8M | 165.97%64.56M | 92.38%20.64M | -13.60%31.89M | 10.50%22.68M | 93.58%-10.65M | ---97.85M | --10.73M | --36.91M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -82.72%3.92M | -351.03%-48.74M | 164.61%64.14M | 94.08%20.38M | -10.87%31.89M | 10.71%22.68M | 93.49%-10.81M | -5,541.14%-99.28M | 2,008.91%10.5M | 19,546.74%35.78M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 6,838.81%75.98M | 5,900.00%60K | 162,058.33%38.92M | -99.17%1.1M | -99.58%1K | -65.22%24K | ||||
| Net common stock issuance | ---- | ---- | --36.76M | --0 | ---123K | ---- | ---- | --0 | --0 | --0 |
| Net preferred stock issuance | ---- | ---- | --40.03M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | ---- | ---- | -87.58%136K | --0 | -37.50%15K | ---- | ---- | 88.14%1.1M | -99.58%1K | -65.22%24K |
| Net other financing activities | ---- | ---- | ---944K | ---39.97M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | 6,838.81%75.98M | 5,900.00%60K | 162,058.33%38.92M | ---- | ---- | -99.17%1.1M | -99.58%1K | -65.22%24K |
| Net cash flow | ||||||||||
| Beginning cash position | 79.23%54.13M | 99.33%121.17M | -73.92%60.79M | 80.37%122.56M | 45.34%71.74M | -36.75%30.2M | -73.92%60.79M | 42.68%233.09M | -72.47%67.95M | -81.37%49.36M |
| Current changes in cash | -120.66%-8.58M | -119.16%-67.04M | 135.04%60.38M | 80.67%-1.38M | 173.39%50.82M | 2,480.06%41.54M | 83.50%-30.59M | -347.11%-172.3M | 47.71%-7.16M | 202.66%18.59M |
| End cash Position | -36.51%45.55M | 79.23%54.13M | 99.33%121.17M | 99.33%121.17M | 80.37%122.56M | 45.34%71.74M | -36.75%30.2M | -73.92%60.79M | -73.92%60.79M | -72.47%67.95M |
| Free cash flow | 31.09%-12.5M | 8.19%-18.3M | -6.11%-80.16M | -23.45%-22.08M | -8.98%-20M | 6.90%-18.14M | -0.60%-19.94M | -21.82%-75.54M | -28.51%-17.89M | -0.97%-18.35M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data